Stockreport

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Pipeline Progress

Arcturus Therapeutics Holdings Inc.  (ARCT) 
Last arcturus therapeutics holdings inc. earnings: 3/11 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.arcturusrx.com/investor-relations
PDF ARCT-032 (CF) Phase 2 third cohort (28 days, 15 mg) generally safe and well toleratedARCT-032 permitted to proceed into 12-week Phase 2 study; dosing to begin H1 2026Cas [Read more]